menu
    • menu
    [{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho Co, Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho Co, Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Maruho Co, Ltd"},{"orgOrder":0,"company":"Insightec","sponsor":"SonALAsense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Insightec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Insightec \/ SonALAsense","highestDevelopmentStatusID":"7","companyTruncated":"Insightec \/ SonALAsense"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Wellcome","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"","sponsorNew":"Biofrontera \/ Wellcome","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Wellcome"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"Ferrochelatase","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"Ferrochelatase","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Roth Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Roth Capital Partners"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"SonALAsense","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SonALAsense","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SonALAsense \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SonALAsense \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Roth Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Roth Capital Partners"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Not Applicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Alpheus Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alpheus Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alpheus Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpheus Medical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Levulan

    Menu

    Levulan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alpheus Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Alpheus Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alpheus Announces Positive Glioma Treatment Phase 1/2 Results

                            Details : Low-Intensity Diffuse Ultrasound with the sensitizing agent, oral 5-aminolevulinic acid (5-ALA) is being investigated in patients with recurrent or refractory high-grade gliomas.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 24, 2024

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $4.2 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

                            Details : The proceeds from this financing will primarily support Biofrontera’s commercial and clinical development initiatives including Ameluz (aminolevulinic acid) for superficial basal cell carcinoma.

                            Brand Name : Ameluz

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 22, 2024

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $4.2 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biofrontera Reports Significant Phase 3 Results for Ameluz®-PDT in Basal Cell Carcinoma

                            Details : Ameluz (Aminolevulinic HCl)is a topical gel, being investigated with the BF-RhodoLED® lamp in the treatment of Superficial Basal Cell Carcinoma.

                            Brand Name : Ameluz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 31, 2024

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biofrontera Completes Database Lock in Ameluz® PDT Study for sBCC

                            Details : Ameluz (5-aminolevulinic acid hydrochloride) is a topical gel that acts as a photosensitizing agent during photodynamic therapy. It is used primarily for the treatmentsuperficial basal cell carcinoma.

                            Brand Name : Ameluz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 14, 2024

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA OKs Triple-Tube Use of Ameluz Gel for Skin Cancer Treatment

                            Details : Ameluz is the only PDT photosensitizer indicated by the FDA for both lesion-directed and field-directed treatment of Actinic Keratosis.

                            Brand Name : Ameluz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 07, 2024

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Roth Capital Partners

                            Deal Size : $16.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Biofrontera Inc. Announces Closing Of Private Placement Of Up To $16.0 Million

                            Details : The Company intends to fund ongoing activities related to expediting the development and approval of additional indications for Ameluz (aminolevulinic acid hydrochloride) to treat actinic keratoses.

                            Brand Name : Ameluz

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Roth Capital Partners

                            Deal Size : $16.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SonALAsense

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            SonALAsense

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SonALAsense Announces Completion of First Cohort in Phase 2 Study of SONALA-001 Sonodynamic Therapy for Recurr...

                            Details : SONALA-001 (aminolevulinic acid) is a porphyrin precursor and optical imaging agent. The mechanism of action of aminolevulinic acid is as a fluorescence contrast activity.

                            Brand Name : SONALA-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 08, 2023

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on...

                            Details : AMELUZ® (aminolevulinic acid hydrochloride) topical gel, 10%, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED® lamp, is indicated for lesion-directed and field-directed treatment of actinic keratoses.

                            Brand Name : Ameluz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 21, 2022

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent

                            Details : AMELUZ (aminolevulinic acid hydrochloride) topical gel, 10%, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED® lamp, is indicated for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moder...

                            Brand Name : Ameluz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 06, 2022

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Biofrontera

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofron...

                            Details : Ameluz (Aminolevulinic Acid Hydrochloride) is utilized along with photodynamic therapy (PDT) provided by the Company’s proprietary lamp devices to form Ameluz®-PDT.

                            Brand Name : Ameluz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 24, 2022

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth